HomeCompareCLBS vs KO

CLBS vs KO: Dividend Comparison 2026

CLBS yields 131.33% · KO yields 2.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBS wins by $12.96M in total portfolio value
10 years
CLBS
CLBS
● Live price
131.33%
Share price
$0.43
Annual div
$0.56
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.99M
Annual income
$5,201,713.69
Full CLBS calculator →
KO
The Coca-Cola Company
● Live price
2.70%
Share price
$76.27
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,303.79
Full KO calculator →

Portfolio growth — CLBS vs KO

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBSKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBS + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLBS pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS
Annual income on $10K today (after 15% tax)
$11,163.23/yr
After 10yr DRIP, annual income (after tax)
$4,421,456.64/yr
KO
Annual income on $10K today (after 15% tax)
$229.58/yr
After 10yr DRIP, annual income (after tax)
$3,658.22/yr
At 15% tax rate, CLBS beats the other by $4,417,798.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + KO for your $10,000?

CLBS: 50%KO: 50%
100% KO50/50100% CLBS
Portfolio after 10yr
$6.51M
Annual income
$2,603,008.73/yr
Blended yield
39.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

CLBS
No analyst data
Altman Z
-42.9
Piotroski
2/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.3% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys
0
KO buys
0
No recent congressional trades found for CLBS or KO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBSKO
Forward yield131.33%2.70%
Annual dividend / share$0.56$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$12.99M$34.1K
Annual income after 10y$5,201,713.69$4,303.79
Total dividends collected$11.90M$15.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CLBS vs KO ($10,000, DRIP)

YearCLBS PortfolioCLBS Income/yrKO PortfolioKO Income/yrGap
1← crossover$23,833$13,133.21$10,846$335.73+$13.0KCLBS
2$54,754$29,252.94$11,829$430.64+$42.9KCLBS
3$121,396$62,809.15$12,988$555.50+$108.4KCLBS
4$260,039$130,144.39$14,372$721.34+$245.7KCLBS
5$538,781$260,539.45$16,049$944.01+$522.7KCLBS
6$1,080,999$504,503.28$18,114$1,246.74+$1.06MCLBS
7$2,102,673$946,004.75$20,702$1,664.24+$2.08MCLBS
8$3,969,574$1,719,713.85$24,008$2,249.48+$3.95MCLBS
9$7,281,647$3,034,202.37$28,317$3,085.19+$7.25MCLBS
10$12,993,076$5,201,713.69$34,065$4,303.79+$12.96MCLBS

CLBS vs KO: Complete Analysis 2026

CLBSStock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this CLBS vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHDCLBS vs JEPICLBS vs OCLBS vs MAINCLBS vs PEPCLBS vs PGCLBS vs JNJCLBS vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.